Mannose Presenting ‘Glyco-Colicins’ Convert the Bacterial Cell Surface into a Multivalent Adsorption Site for Adherent Bacteria

17 April 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Biofilm formation is integral to the pathogenesis of numerous adherent bacteria and contributes to antimicrobial resistance (AMR). The rising threat of AMR means the need to develop novel non-bactericidal anti-adhesion approaches against such bacteria is more urgent than ever. Both adherent invasive Eschericia coli (AIEC, implicated in inflammatory bowel disease) and uropathogenic E. coli (UPEC, responsible for ~80% of urinary tract infections) adhere to terminal mannose sugars on epithelial glycoproteins through the FimH adhesin on their type 1 pilus. Although mannose-based inhibitors have previously been explored to inhibit binding of adherent bacteria to epithelial cells, this approach has been limited by monovalent carbohydrate-protein interactions. Herein we pioneer a novel approach to this problem through the preparation of colicin E9 bioconjugates that bind to the abundant BtuB receptor in the outer membrane of bacteria, enabling multivalent presentation of functional motifs on the cell surface. We show these bioconjugates label the surface of live E. coli, and furthermore demonstrate that mannose presenting “glyco-colicins” induce E. coli aggregation, using the bacteria itself as a multivalent platform for mannose display which triggers binding to adjacent FimH presenting bacteria.

Keywords

carbohydrates
mannose
neoglycoproteins
FimH bacterial aggregation
bioconjugation

Supplementary materials

Title
Description
Actions
Title
Supporting information
Description
Supporting information
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.